Aseries of disclosures in recent weeks revealed fraud and bribery in the Food and Drug Administration's (FDA) generic drug approval programs. Some lawmakers have reacted to these disturbing developments by calling for stricter FDA review of new drug approvals. FDA!sfeall problem, however, remains a drug approval process that moves too slowly, not too quickly. Over the past year, the FDA has taken several significant steps toward making new drugs available more quickly to those who need them most, such as sufferers of potentially fatal diseases, includ- ing AIDS. Only last week, for example, the FDA approved wide distribution of the anti-AIDS drug DDI, even though tests of the drug's effectiveness and side effects have not yet been com- pleted. The recent scandals should not be used as an excuse to halt or slow these actions.
(Archived document, may contain errors) 948 June 29,1993 MANAGED COMPETITION LESS CHOICE AND COMPETIIION By Peter J. Fe rrara Senior Fellow INTRODUCTION while the Clinton Administration continues to shape its health care proposal, several key Members of Congress-in both parties-have been developing comprehensive health care reform proposals loosely based on the concept of managed competition.
Estimating the total benefits and costs of federal regulations - asOMB is required to do in this report - is no easy task. Regulatoryaccounting is still an evolving, and as yet imperfect, discipline.Yet, there are some changes that could usefully be made to providea clearer and more complete picture of the impact of regulation.
Supreme Court EPA ruling might have sweeping impact to restrict the administrative state. Actions involving the SEC, FCC and crypto might all be reined in.